Currently available literature investigating the role of PSMA PET in biochemical recurrent prostate cancer is highly heterogeneous regarding patients’ characteristics, as they include subjects treated with either surgery or radiotherapy for primary PCa, and both patients with and without hormonal therapy during biochemical recurrence. Here, FOLH1 is linked to prostate cancer.